ABSTRACT
Objective: To investigate the expression and prognostic significance of insulin-like growth factor binding protein 5 (IGFBP5) in gastric adenocarcinoma (GAC). Methods:IGFBP5 expression in tissue samples from 236 GAC patients was analyzed us-ing immunohistochemical methods. These patients had undergone surgical resection between 20003 and 2006 in Sun Yat-Sen Universi-ty Cancer Center. The relationship between IGFBP5 expression and clinicopathological factors in the 236 GAC patients was analyzed using Pearson correlation analysis. The significance of IGFBP5 in predicting the survival status of these patients was analyzed using Ka-plan-Meier survival analysis and Cox's proportional hazards regression model. Results:Immunohistochemical staining data indicated that IGFBP5 expression was significantly decreased in 159 of the total GAC cases (67.4%). Of the 62 cases with well-and moderately differentiated GAC, 31 (50%) exhibited reduced IGFBP5 expression. Of the 174 cases with poorly differentiated GAC, 128 showed re-duced IGFBP5 expression. Reduced IGFBP5 expression was also observed in female patients and in patients with tumors over 5 cm in size or with poorly differentiated tumors (P<0.05). The reduced expression of IGFBP5 was common in the tumors that were staged as T3+4a/b andⅢ/Ⅳ(P<0.05). Kaplan-Meier survival analysis revealed that the reduced expression of IGFBP5 was associated with poor prognosis in GAC patients (P<0.001). Cox regression analysis identified IGFBP5 expression as an independent prognostic factor for the overall survival of these cancer patients (HR=1.897, P=0.029). Conclusion: IGFBP5 expression is reduced in GAC tissues, and IGFBP5 independently predicts an unfavorable prognosis in GAC patients.
ABSTRACT
Objective To evaluate the efficacy and safety of the hyper-CVAD/MA regimen as an intensified treatment option for 28 T cell and aggressive/highly aggressive B cell NHL in Chinese patients. Methods Clinical data of 28 NHL patients treated with hyper-CVAD/MA regimen from Jan 2005 to Sep 2008 were retrospectively analyzed. Results 27 NHL patients were available for the efficacy analysis, with a response rate of 70.4 %. For the 13 B cell lymphoma cases, the response rate was 84.6 %. The main toxicity was Grade Ⅲ or Grade Ⅳ myelosuppression in all cases and 2 treatment related deaths. Conclusion Hyper-CVAD/MA regimen had a high response rate in T cell and aggressive /highly aggressive B cell NHL lymphoma, companied by significant toxicity when treating Chinese patients. Further clinical practices are needed to pick up a suitable dose which can balance efficacy and safety.